Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)

Guillermo Garcia-Manero, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Lambert Busque, MD, Richard A. Wells, MD DPhil, Olatoyosi Odenike, MD, David P. Steensma, MD, Karen W.L. Yee, MD, Stefan Faderl, Philip C. Amrein, MD, Laura C. Michaelis, MD, Hagop M. Kantarjian, MD, Aram Oganesian, James N. Lowder, MD, Mohammad Azab, MD, Michael R. Savona, MD

Blood (2017) 130 (Supplement 1): 4274.

https://doi.org/10.1182/blood.V130.Suppl_1.4274.4274

Published: 2017

Journal Articles

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

Guillermo Garcia-Manero, MD, Olatoyosi Odenike, MD, Philip C. Amrein, MD, David P. Steensma, MD, Amy E. DeZern, MD MHS, Laura C. Michaelis, MD, Stefan Faderl, MD, Hagop M. Kantarjian, MD, James N. Lowder, MD, Pietro Taverna, PhD, Aram Oganesian, PhD, Xiaoping Zhang, PhD, Mohammad Azab, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 114.

https://doi.org/10.1182/blood.V128.22.114.114

Published: 2016

Journal Articles

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Michael R. Savona, MD, Olatoyosi Odenike, MD, Philip C. Amrein, MD, David P. Steensma, MD, Wael A. Harb, MD, Amy E. DeZern, MD MHS, Laura C. Michaelis, MD, Stefan Faderl, MD, James N. Lowder, MD, Pietro Taverna, PhD, Aram Oganesian, PhD, Richa Dua, PharmD, Roya Nawabi, Mohammad Azab, MD, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 1683.

https://doi.org/10.1182/blood.V126.23.1683.1683

Published: 2015

Journal Articles

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Blood (2015) 126 (23): 458.

https://doi.org/10.1182/blood.V126.23.458.458

Published: 2015

Journal Articles

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

James N. Lowder, MD, Jonathan W. Freidberg, MD, Jennifer Kelly, Arnold S. Freedman, MD, Robert Coffman, PhD, Holger Kanzler, PhD, Paul Sims, Jimmy Hwang, MD, Nicholas Haining

Blood (2007) 110 (11): 3844.

https://doi.org/10.1182/blood.V110.11.3844.3844

Published: 2007

NARROW

A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

Email alerts

ASH Publications

American Society of Hematology

A Phase 2 Dose-Confirmation Study of Oral ASTX727, a Combination of Oral Decitabine with a Cytidine Deaminase Inhibitor (CDAi) Cedazuridine (E7727), in Subjects with Myelodysplastic Syndromes (MDS)

Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study

Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Comparison of Efficacy and Safety Results in 103 Treatment-Naïve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA)

Dose Finding in Human Trials of TLR9 Agonists: Induction of Interferon-α Inducible Genes in Blood Mononuclear Cells as a Measure of Biologic Activity of 1018 ISS.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only